No, 70-year-old men do NOT have a lower risk of developing prostate cancer
Men aged 70 years and older actually have a HIGHER risk of developing more aggressive prostate cancer compared to younger men, though the clinical significance and benefit of screening at this age becomes more nuanced.
The Evidence on Risk at Age 70
The data consistently demonstrates that older men face increased prostate cancer risk with more aggressive features:
Men older than 70 years are more likely to present with higher grade and stage disease compared to younger counterparts, with significantly worse pathological features including higher Gleason scores, larger tumor volumes, and more advanced pathological stages 12
In a cohort of 4,561 men who underwent radical prostatectomy, those over 70 had a 52.1% rate of pathological stage 3/4 disease versus 33.0% in men under 60, and 17.2% had Gleason sum >7 versus 9.5% in younger men 1
The prevalence of clinically significant prostate cancer increases with age, not decreases 33
Why Screening Recommendations Change After 70
The shift in screening recommendations at age 70 is NOT because risk decreases, but rather because:
The Balance of Benefit vs. Harm Shifts
A large proportion of men over 70 harbor cancers that would be unlikely to affect their life expectancy due to competing mortality risks 44
Screening in this population substantially increases rates of overdiagnosis (detecting cancers that would never cause symptoms or death) 33
The microsimulation models show that decreasing screening age from 74 to 69 years leads to a 27% reduction in lives saved but almost 50% reduction in overdiagnosis 44
Life Expectancy Becomes the Critical Factor
Only men with >10-15 years life expectancy should be screened at any age 445. At age 70+, comorbidities and competing mortality risks often mean the window for benefit from early detection narrows considerably.
Current Guideline Recommendations for Age 70
PSA testing should be individualized after age 70 years with careful evaluation 44:
Testing should be performed with caution and only in very healthy men with little or no comorbidity 44
The NCCN supports screening until age 75, then continuing only in very select patients (Category 2B) 33
Men aged 75-80 years with PSA <3.0 ng/mL are unlikely to die of or experience aggressive prostate cancer and may safely discontinue screening 446
The US Preventive Services Task Force recommends against screening for men ≥70 years 5
The PSA-Based Risk Stratification Approach
For men who do continue screening past 70:
Consider increasing the PSA threshold for biopsy (rather than the standard 4.0 ng/mL cutoff) to reduce overdiagnosis while maintaining detection of clinically significant disease 44
Recent PSA values (age 65-69) are highly predictive: Men with PSA <1.0 ng/mL at ages 65-69 have very low 10-year prostate cancer mortality risk (0.10%), even among Black men in the healthiest quintile 7
Clinical Pitfalls to Avoid
Don't confuse decreased screening recommendations with decreased cancer risk - older men have MORE aggressive disease when diagnosed
Don't screen men with <10 year life expectancy regardless of age - use validated tools to estimate life expectancy, not just chronological age 33
Don't ignore the 30-40% of men over 70 who present with high-risk cancers that pose clinically significant risk if left undetected 44
Don't apply population-level screening recommendations rigidly - very healthy 70-year-olds with concerning PSA trends may still benefit from continued surveillance
The key takeaway: 70-year-old men face HIGHER prostate cancer risk with more aggressive disease features, but the benefit of screening decreases due to competing mortality and overdiagnosis concerns, not because cancer risk diminishes.